Paragonix Technologies Receives FDA 510(k) Clearance for KidneyVault Portable Renal Perfusion System
WALTHAM, Mass.--(BUSINESS WIRE)--Paragonix Technologies, a pioneer in organ transplant technologies and organ procurement services, received U.S. Food and Drug Administration (FDA) 510(k) clearance ...
WALTHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Paragonix Technologies, a leader in advanced organ preservation and transplant logistics, reports an extraordinary case at the Tampa General Hospital ...
New Modes Are Beginning to Gain Ground on Fed-batch Strategy The therapeutic success of highly efficacious complex biologicals that are almost exclusively produced in cell culture such as antibodies ...
WALTHAM, Mass.--(BUSINESS WIRE)--Paragonix Technologies, a pioneer in organ transplant technologies and organ procurement services, announced today the completion of the world’s first donor kidney ...
ANDOVER, Mass., Aug. 2, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...
PLYMOUTH, Mich., Feb. 20, 2026 /PRNewswire/ -- Orrum Clinical Analytics today announced a strategic partnership with LivaNova USA Inc. to connect LivaNova's Essenz™ Perfusion System to the analytics ...
27 April 2025, Boston—In places like Australia, where metropolitan areas are separated by an entire continent, donor hearts used to go unused simply because transplant teams couldn’t get the organ to ...
Most people in need of a kidney wait three to five years on a national transplant list in the United States, according to the National Kidney Foundation. The most current list has more than 103,000 ...
Siemens Healthineers announced today that it entered into a global collaboration with Cercare Medical for acute stroke care.
A new medical technology expected to be on the market in 2027 is poised to help patients in middle America have greater access to heart transplants. Xvivo Perfusion, a leader in organ transplant ...
FUJIFILM Biosciences, announced the commercial launch of BalanCD HEK293 Perfusion A. Designed to expand and augment the company’s portfolio of gene therapy application solutions, BalanCD HEK293 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results